Leuprolide (Leuprorelin)

Description

Leuprolide (Leuprorelin)

Also known as: Lupron, Eligard, Leuprorelin

Leuprolide first triggers and then reduces the release of gonadotropins by continuously activating GnRH receptors. Following an initial surge in hormone levels, it results in decreased testosterone and estrogen production. This produces a temporary, reversible state similar to surgical castration.
Approved by the FDA for several uses.

• A GnRH agonist that reduces the production of testosterone and estrogen. Approved by the FDA for treating prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
• Status: Approved by the FDA. Evidence level: Confirmed through FDA approval.
• Typical dosage: Varies based on formulation—available as daily, monthly, or 3- to 6-month regimens. Administered via intramuscular or subcutaneous depot injection.
• Investigated for use in: Prostate cancer, endometriosis, and general hormone suppression.